Bioxcel Therapeutics (BX20) Stock Statistics & Valuation Metrics
Total Valuation
Bioxcel Therapeutics has a market cap or net worth of EUR 363.88K. The enterprise value is EUR 133.37M.
- Market Cap
- EUR 363.88K
- Enterprise Value
- EUR 133.37M
Share Statistics
Bioxcel Therapeutics has 31,305,498 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 31,305,498
- Owned by Insiders
- 2.75%
- Owned by Institutions
- 9.67%
Financial Efficiency
Bioxcel Therapeutics’s return on equity (ROE) is 0.73 and return on invested capital (ROIC) is -314.44%.
- Return on Equity (ROE)
- 0.73
- Return on Assets (ROA)
- -1.56
- Return on Invested Capital (ROIC)
- -314.44%
- Return on Capital Employed (ROCE)
- 5.58
- Revenue Per Employee
- 22.14K
- Profits Per Employee
- -2.41M
- Employee Count
- 29
- Asset Turnover
- 0.01
- Inventory Turnover
- 0.23
Valuation Ratios
The current PE Ratio of Bioxcel Therapeutics is -0.01. Bioxcel Therapeutics’s PEG ratio is -0.00.
- PE Ratio
- -0.01
- PS Ratio
- 3.08
- PB Ratio
- -0.01
- Price to FCF
- -0.04
- Price to Operating Cash Flow
- -0.02
- PEG Ratio
- -0.00
Income Statement
In the last 12 months, Bioxcel Therapeutics had revenue of 642.00K and earned -69.90M in profits. Earnings per share was -5.73.
- Revenue
- 642.00K
- Gross Profit
- 478.00K
- Operating Income
- -50.27M
- Pretax Income
- -69.90M
- Net Income
- -69.90M
- EBITDA
- -52.61M
- Earnings Per Share (EPS)
- -5.73
Cash Flow
In the last 12 months, operating cash flow was -50.90M and capital expenditures 0, giving a free cash flow of -50.90M billion.
- Operating Cash Flow
- -50.90M
- Free Cash Flow
- -50.90M
- Free Cash Flow per Share
- -4.17
Dividends & Yields
Bioxcel Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -2230.82%
- Earnings Yield
- -7854.39%
Stock Price Statistics
- Beta
- 0.85
- 52-Week Price Change
- -96.15%
- 50-Day Moving Average
- 0.12
- 200-Day Moving Average
- 0.81
- Relative Strength Index (RSI)
- 20.29
- Average Volume (3m)
- 14.41K
Important Dates
Bioxcel Therapeutics upcoming earnings date is Nov 18, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 11, 2026
- Next Earnings Date
- Nov 18, 2026
- Ex-Dividend Date
- ―
Financial Position
Bioxcel Therapeutics as a current ratio of 0.83, with Debt / Equity ratio of -114.87%
- Current Ratio
- 0.83
- Quick Ratio
- 0.82
- Debt to Market Cap
- 5.61
- Net Debt to EBITDA
- -1.54
- Interest Coverage Ratio
- -2.96
Taxes
In the past 12 months, Bioxcel Therapeutics has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Bioxcel Therapeutics EV to EBITDA ratio is -1.76, with an EV/FCF ratio of -1.84.
- EV to Sales
- 126.54
- EV to EBITDA
- -1.76
- EV to Free Cash Flow
- -1.84
- EV to Operating Cash Flow
- -1.84
Balance Sheet
Bioxcel Therapeutics has EUR 12.84M in cash and marketable securities with EUR 104.45M in debt, giving a net cash position of -EUR 91.61M billion.
- Cash & Marketable Securities
- EUR 12.84M
- Total Debt
- EUR 104.45M
- Net Cash
- -EUR 91.61M
- Net Cash Per Share
- -EUR 2.93
- Tangible Book Value Per Share
- -EUR 9.46
Margins
Gross margin is 45.28%, with operating margin of -6014.42%, and net profit margin of -9549.87%.
- Gross Margin
- 45.28%
- Operating Margin
- -6014.42%
- Pretax Margin
- -9549.87%
- Net Profit Margin
- -9549.87%
- EBITDA Margin
- -7198.25%
- EBIT Margin
- -7228.57%
Analyst Forecast
The average price target for Bioxcel Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -20.79%
- EPS Growth Forecast
- 68.82%
